Background {#Sec1}
==========

Cancer is one of the most serious diseases threatening human health and has become a major public health problem \[[@CR1]\]. Cancers are heterogeneous in nature; each type of cancer is associated with many unique epigenetic and genetic variations \[[@CR2]\]. Studies exploring the processes of tumor development and those that investigate specific cancer expression profiles offer invaluable insight into both the molecular underpinnings of the disease and the potential diagnostic and therapeutic targets for use in patients \[[@CR3]\]. Irreparable structural mutations in cells are the main cause of human cancer; these alter the DNA copy number and function of a gene at a very specific genomic location. Identifying copy number alterations is a useful approach for linking copy number alterations (CNAs) with the disease phenotype. Thus, the current study offers cell-level insight into the genetic and epigenetic changes influencing the altered biochemical processes observed in tumor cells.

Secreted phosphoprotein 1 (SPP1), also named Osteopontin (OPN), is an integrin-binding protein that is secreted from various types of cells, including macrophages, endothelial cells, and osteoclasts. In humans, SPP1 is composed of 6 introns and 7 exons, and is encoded on chromosome 4 (4q13) \[[@CR4]\]. SPP1 is involved in multiple physiological and pathological processes. Recent studies have reported that SPP1 is significantly associated with cell growth, adherence and invasion in tumourigenesis and metastasis, and is over-expressed in lung \[[@CR5]\], colon \[[@CR6]\], breast \[[@CR7]\], and prostate cancers \[[@CR8]\]. The expression level of SPP1 correlates with tumor stage and aggressiveness, suggesting that OPN may be a diagnostic and prognostic biomarker for several cancers. On the other hand, secreted phosphoprotein 2 (SPP2) is a bone matrix protein that can bind to and inhibit the bone morphogenetic proteins (BMPs) inducing bone formation. The SPP2 gene spans approximately 27 kb at chromosome 2 (2q37.1) and encodes secreted phosphoprotein 24 kD \[[@CR9]\]. Cancers are often associated with misregulation of the BMP signaling pathway. Previous studies have shown that SPP2 inhibits the growth of tumor cells in prostate cancer \[[@CR10]\], pancreatic cancer \[[@CR9]\] and hepatocellular carcinoma \[[@CR11]\] and attenuates the growth-enhancing effects of BMP2. Thus, we hypothesize that SPP plays an oncogenic or anti-oncogenic function in different cancers. To explore the character of SPP members in cancers, oncomine platform assesses the gene expression of cancer by 86,733 microarray experiments. Furthermore, the survival of cancer patients was analyzed by PrognoScan database. The co-expression data revealed the biological function and provided insight into the potential underlying mechanism. The gene ontology enrichment by STRING is able to discover the function and regulatory mechanism of genes. Basing on many available database results pertaining to changes in gene expression or copy number, we conducted a deep analysis of alterations in SPP gene expression or copy number in the tumors of cancer patients. The goal of this analysis was to understand how the expression and mutation of these genes are associated with patient outcomes.

Materials and methods {#Sec2}
=====================

Oncomine data analysis {#Sec3}
----------------------

Data sets available within the Oncomine database (<https://www.oncomine.org>), which compiles previously published microarray data, were employed in order to assess SPP expression patterns in different types of cancer. For each dataset we assessed comparisons of mRNA expression between tumor and normal tissue based on the following thresholds: *p*-value \<1E-4, fold change \> 2. We only identified the top 10% of differentially expressed genes, and using the compiled data we generated heat maps of differential SPP gene expression in different cancer types.

Prognoscan database analysis {#Sec4}
----------------------------

Using the PrognoScan database (<http://dna00.bio.kyutech.ac.jp/PrognoScan/>), we assessed the relationsip between SPP gene expression and survival in different cancer types, using a cox p-value threshold of \< 0.05 \[[@CR12]\].

Protein-protein interaction (PPI) network construction {#Sec5}
------------------------------------------------------

In order to better understand molecular mechanisms governing carcinogenesis, we employed the STRING database to generate a PPI network for SPP genes. We used a minimum interaction score of at least 0.4 as a cut-off when visualizing this network.

cBioPortal database analysis {#Sec6}
----------------------------

We additionally employed the open-access cBioPortal for Cancer Genomics database, which is available to assist with visualization and interpretation of large cancer genomic data (<http://www.cbioportal.org/>) \[[@CR13], [@CR14]\]. We were thereby able to review records from 215 separate studies covering 31 cancers and over 66,000 total samples. Our main parameters for exploring RNA-seq datasets with this database included SPP gene alterations (amplifications, deletions, or missense mutations) and Copy Number alterations (CNAs).

Statistical analysis {#Sec7}
--------------------

All results are displayed with *p* values from a log-tank test. Survival curves were generated by the PrognoScan database, using a cox *p*-value threshold of \< 0.05. Statistical significance of the data (*p*-values) was provided by the program.

Results {#Sec8}
=======

The expression of SPP1 and SPP2 in various cancers {#Sec9}
--------------------------------------------------

To assess the importance of SPP in various cancers, SPP1 and SPP2 expression were analyzed in healthy and tumor tissues via the Oncomine database. We found that SPP1 was upregulated in breast, bladder, colorectal, head and neck, liver cancer, lung, and esophageal cancers, whereas decreased in kidney cancer and sarcoma (*p* \< 0.05, Fig.[1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). SPP2 was under-expressed in colorectal cancer, leukemia, liver cancer and pancreatic cancer (*p* \< 0.05, Fig.[1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). We additionally utilized Oncomine database to confirm SPP expression in various forms of cancer (*p* \< 0.05, Fig.[2](#Fig2){ref-type="fig"} and Fig.[3](#Fig3){ref-type="fig"}). We found that in certain cancers SPP1 was over-expressed, while in others it was under-expressed, suggesting that depending on the particular cancer type SPP1 may be playing a pro- or anti-oncogneic function. However, SPP2 is generally lowly expressed in tumors, suggesting that SPP2 may serve as tumor suppressor gene. Fig. 1The transcription levels of SPP1 and SPP2 in different types of cancers, This graphic was generated from Oncomine, indicating the numbers of datasets with statistically significant mRNA over-expression (Red) or down-expression (Blue) of SPP1 and SPP2 in cancer versus normal tissue.The threshold was designed with following parameters: p-value of 1E-4, fold change of 2, and gene ranking of 10% Table 1SPP1 expression in cancersCancerCancer subtype*P* valueFold changeSampleReferenceLungLung Adenocarcinoma6.73E-3820.61610718,297,132Squamous Cell Lung Carcinoma5.67E-760.24520311,707,567colonColon Mucinous Adenocarcinoma7.35E-1135.19410517,615,082Colon Adenocarcinoma1.50E-1113.17010517,615,082CervixCervical Squamous Cell Carcinoma1.93E-1518.8376618,506,748BrainGlioblastoma1.03E-62.3465416,204,036Head-NeckHead and Neck Squamous Cell Carcinoma1.31E-2043.6145414,729,608Oral Cavity Squamous Cell Carcinoma8.04E-2411.2157921,853,135Tongue Squamous Cell Carcinoma2.52E-915.5285819,138,406OvarianOvarian Serous Adenocarcinoma3.12E-525.6231614,760,385GastricGastric Cancer2.52E-104.04216020,965,966Gastric Intestinal Type Adenocarcinoma2.58E-1315.5199619,081,245EsophagusEsophageal Squamous Cell Carcinoma1.99E-229.15410621,385,931BreastInvasive Ductal Breast Carcinoma Stroma2.87E-516.3372217,914,389Invasive Breast Carcinoma7.36E-64.068213622,522,925Tubular Breast Carcinoma4.30E-194.813213622,522,925BladderInfiltrating Bladder Urothelial Carcinoma1.19E-146.22915716,432,078LiverHepatocellular Carcinoma1.66E-107.50511519,098,997LymphomaPrimary Effusion Lymphoma6.97E-8137.97933615,778,709Centroblastic Lymphoma2.66E-912.80333615,778,709Diffuse Large B-Cell Lymphoma5.55E-1812.09613619,412,164Unspecified Peripheral T-Cell Lymphoma1.31E-98.7396017,304,354ProstateProstate Carcinoma1.95E-53.00412222,722,839Prostate Adenocarcinoma1.23E-42.1854012,873,976MelanomaCutaneous Melanoma6.43E-813.3227018,254,958PancreasPancreatic Ductal Adenocarcinoma4.26E-116.6197816,204,036Pancreatic Intraepithelial Neoplasia3.10E-51.8273816,103,885SarcomaMyxofibrosarcoma1.01E-46.2874020,601,955KidneyClear Cell Sarcoma of the Kidney3.07E-5−3.9343516,299,227 Table 2SPP2 expression in cancersCancerCancer subtype*P* valueFold changeSampleReferenceBreastInvasive Lobular Breast Carcinoma0.0022.5983017,389,037Mucinous Breast Carcinoma0.0456.717593TCGALungMicropapillary Lung Adenocarcinoma0.0031.0461537TCGALung Adenocarcinoma8.83E-72.34124622,080,568EsophagusBarrett's Esophagus0.0231.2305216,449,976ProstateProstate Carcinoma3.36E-41.13710212,086,878PancreasPancreatic Adenocarcinoma4.68E-51.033100TCGALymphomaT-Cell/Histiocyte-Rich Large B-Cell Lymphoma0.0111.2206718,794,340Diffuse Large B-Cell Lymphoma0.0091.1326718,794,340Burkitt's Lymphoma0.0311.1956718,794,340Follicular Lymphoma0.0351.1676718,794,340MelanomaSkin Basal Cell Carcinoma0.0062.7638718,442,402Pleural Malignant Mesothelioma0.0162.1955415,920,167Skin Squamous Cell Carcinoma0.0481.9068718,442,402BrainPrimary Glioblastoma0.0051.03518718,077,431GastricGastric Mixed Adenocarcinoma0.0081.0709021,447,720ThyroidThyroid Gland Oncocytic Follicular Carcinoma0.0451.1049916,609,007LiverHepatocellular Carcinoma1.18E-42−5.79044521,159,642ColonRectal Adenocarcinoma3.58E-4−1.824237TCGAColon Adenocarcinoma6.61E-4−1.658237TCGAOvarianOvarian Mucinous Adenocarcinoma0.0241.08510316,452,189Colon Adenocarcinoma1.10E-5−2.94112317,640,062PancreasPancreatic Carcinoma0.003−1.4111715,867,264Pancreatic Ductal Adenocarcinoma1.88E-8−1.3687819,260,470 Fig. 2The expression level of SPP1 in different cancer types (Oncomine database), The box plot comparing specific SPP1 expression in normal (left plot) and cancer tissue (right plot) was derived from Oncomine database. The fold change of SPP1 in various types of cancers was identified from our analyses in Table [1](#Tab1){ref-type="table"} Fig. 3The expression level of SPP2 in different cancer types (Oncomine database), The box plot comparing specific SPP2 expression in normal (left plot) and cancer tissue (right plot) was derived from Oncomine database. SPP2 was under-expressed in colon carcinoma (**a**), hepatocellular carcinoma (**b**), pancreatic cancer (**c**), and leukemia (**d**). The fold change of SPP2 in various types of cancers was identified from our analyses in Table [2](#Tab2){ref-type="table"}

SPP expression is associated with survival in various cancers {#Sec10}
-------------------------------------------------------------

Using a Prognostic database, we assessed the predictive link between SPP expression and patient survival in various cancer types. Patients who had a high expression of SPP1 showed poor prognosis in melanoma and in blood, brain, breast, colorectal, and lung cancer (*p* \< 0.05, Fig.[4](#Fig4){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"} and Table [3](#Tab3){ref-type="table"}). The overexpression of SPP2 was linked with reduced survival in those with ovarian cancer, whereas it was linked with improved survival in breast and lung cancer patients (*p* \< 0.05, Fig.[5](#Fig5){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"} and Table [4](#Tab4){ref-type="table"}). Fig. 4The association between the expression of SPP1 gene and prognosis in blood cancer, brain cancer, breast cancer, colorectal cancer, lung cancer and melanoma (PrognoScan database), The survival curve comparing the patient with high (red) and low (blue) expression was plotted from PrognoScan database. The survival curve comparing the patient with high (red) and low (blue) expression in blood cancer (**a**), brain cancer (**b**), breast cancer (**c**), colorectal cancer (**d**), lung cancer (**e**) and melanoma (**f**) was plotted from PrognoScan database as the threshold of cox *p*-value \< 0.05 Table 3The association of SPP1 expression and the survival in cancer patientsCancerNCox *p*-valueHREndpointDatasetProbe IDBladder1650.0275731.24Disease Specific SurvivalGSE13507ILMN_1651354Blood790.0340271.38Overall SurvivalGSE12417-GPL570209875_s\_atBrain500.0113101.32Overall SurvivalMGH-glioma34342_s\_at500.0142651.27Overall SurvivalMGH-glioma2092_s\_at740.0013762.44Overall SurvivalGSE4412-GPL96209875_s\_atBreast1550.0492360.83Overall SurvivalGSE98934002860.0269361.27Distant Metastasis Free SurvivalGSE2034209875_s\_at1590.0012861.71Overall SurvivalGSE1456-GPL96209875_s\_at1590.0115671.5Relapse Free SurvivalGSE1456-GPL96209875_s\_at1590.0052571.73Disease Specific SurvivalGSE1456-GPL96209875_s\_at1980.0324681.22Overall SurvivalGSE7390209875_s\_atColorectal620.04118061.46Overall SurvivalGSE12945209875_s\_at1770.00770451.33Disease Specific SurvivalGSE17536209875_s\_at1770.03325071.34Overall SurvivalGSE175361568574_x\_at1770.01443181.45Disease Specific SurvivalGSE175361568574_x\_at1770.02023431.23Overall SurvivalGSE17536209875_s\_at1450.001403641.56Disease Free SurvivalGSE17536209875_s\_at2260.001356181.40Disease Free SurvivalGSE14333209875_s\_at490.0304531.45Disease Specific SurvivalGSE175371568574_x\_at550.01633471.31Overall SurvivalGSE17537209875_s\_at550.001497791.52Disease Free SurvivalGSE17537209875_s\_at490.03108561.38Disease Specific SurvivalGSE17537209875_s\_at550.0002821641.72Disease Free SurvivalGSE175371568574_x\_atLung1040.01224531.67Overall Survivaljacob-00182-MSK209875_s\_at2040.0002479272.45Overall SurvivalGSE31210209875_s\_at2043.04E-062.18Relapse Free SurvivalGSE31210209875_s\_at2040.0006164391.96Overall SurvivalGSE312101568574_x\_at2044.89E-051.77Relapse Free SurvivalGSE312101568574_x\_at1380.01196771.23Relapse Free SurvivalGSE8894209875_s\_at1380.02147651.25Relapse Free SurvivalGSE88941568574_x\_at1290.03951.51Overall SurvivalGSE4573209875_s\_atSkin380.04344552.6Overall SurvivalGSE19234209875_s\_at Fig. 5The association between the expression of SPP2 and prognosis in Breast, Ovarian and Lung cancers (PrognoScan database), The survival curve comparing the patient with high (red) and low (blue) expression was plotted from PrognoScan database. The survival curve comparing the patient with high (red) and low (blue) expression in breast cancer (**a,b**), ovarian cancer (**c**) and lung cancer (**d**) was plotted from PrognoScan database as the threshold of cox p-value \< 0.05 Table 4The association of SPP2 expression and the survival in cancer patientsCancerNCox *p*-valueHREndpointDatasetProbe IDBreast2000.004603710.62Distant Metastasis Free SurvivalGSE11121214478_at600.004259130.01Relapse Free SurvivalGSE137917,157Colorectal1770.04717940.18Disease Specific SurvivalGSE17536214478_atLung860.04458640.58Overall SurvivalMICHIGAN-LCU20530_atOvarian1330.011664317.00Overall SurvivalDUKE-OC214478_at

Molecular functional pathways and process of SPP1 and SPP2 {#Sec11}
----------------------------------------------------------

We use the String database to predict the ten proteins that interact with the SPP1 and SPP2, respectively. For SPP1 these included (with the corresponding gene names): Tumor Protein P53 (TP53), Matrix Metallopeptidase 3 (MMP3), Matrix Metallopeptidase 7 (MMP7), CD44, Bone Gamma-Carboxyglutamate Protein (BGLAP), Integrin Subunit Beta 1 (ITGB1), Integrin Subunit Beta 3 (ITGB3), Integrin Subunit Beta 5 (ITGB5), Integrin Subunit Alpha 5 (ITGA5), and Integrin Subunit Alpha V (ITGAV). For SPP2 these included (with the corresponding gene names): Fibrinogen Gamma Chain (FGG), Fibrinogen Alpha Chain (FGA), Fibrinogen Beta Chain (FGB), Histidine Rich Glycoprotein (HRG), Alpha 2-HS Glycoprotein (AHSG), Plasminogen (PLG), Orosomucoid 1 (ORM1), Orosomucoid 2 (ORM2), Albumin (ALB), and Hepatocyte Growth Factor (HGF). The biological pathways and process were calculated by Funrich software, and PPI network was generated from STRING online tool (Fig.[6](#Fig6){ref-type="fig"}). Fig. 6Molecular functional pathways and process of SPP1 and SPP2, Interacting nodes are displayed in colored circles using String online tools (**a, c**). Pie chart for illustration of SPP1 (**b**) and SPP2 (**d**) molecular pathways and process was analyzed by Funrich software. Most of the primary biological processes of SPP genes and 10 predicted genes were the mTOR signaling pathway and class I PI3K signaling events, along with the main process of cell growth and maintenance, signaling transduction, cell communication, and protein metabolism

Mutations and copy number alterations of SPP genes in different cancers {#Sec12}
-----------------------------------------------------------------------

We analyzed SPP1 gene mutations and copy number alterations by via assessing 198 studies using the cBioportal tool. We observed a clear amplification pattern in prostate cancer, whereas mutations in SPP1 primarily occurred in cutaneous melanoma and endometrial cancer. The ratio of alteration ranged from 1.03 to 9.23% (Fig.[7](#Fig7){ref-type="fig"}a). For SPP2 gene, an amplification pattern of interest was also observed in prostate cancer. Also, SPP2 mutation was most predominant in cutaneous melanoma and endometrial cancer. The frequency of alteration ranged from 1.06 to 10.77% (Fig.[7](#Fig7){ref-type="fig"}b). Fig. 7Copy number alteration of SPP genes and cancer subtypes, The alteration frequency of SPP1 (**a**) and SPP2 (**b**) was determined by cBioPortal database. The alteration frequency included deletions (blue), amplification (red), Fusion (purple) or mutation (green)

SPP co-expression profiles in different cancers {#Sec13}
-----------------------------------------------

Oncomine was used to analys SPP co-expression. SPP1 co-expression profiles were determined in 41 head-neck squamous cell carcinoma and 13 normal tissues. The results showed that SPP1 was over-expressed in patients with head-neck cancer, and the top 3 genes co-expressing with SPP1 were Matrix Metallopeptidase 9 (MMP9), Actin Related Protein 2/3 Complex Subunit 1B (ARPC1B) and Amyloid Beta Precursor Protein (APP) (Fig.[8](#Fig8){ref-type="fig"} a). The co-expression profile of SPP2 was identified in 22 hepatocellular carcinoma and 21 normal tissues. However, SPP2 was down-regulated in liver cancer. The top 3 genes co-expressing with SPP2 were Leukocyte Cell Derived Chemotaxin 2 (LECT2), Carbamoyl-Phosphate Synthase 1 (CPS1) and Ribokinase (Fig.[8](#Fig8){ref-type="fig"} b). Fig. 8Co-expression profiles of SPP genes in different types of cancers, (**a**) SPP1 genes in head-neck squamous cell carcinoma. SPP1 is coexpressed with the indicated genes across a panel of 41 head-neck squamous cell carcinoma and 13 normal tissues. Bar length represented the significance and negative logarithm of enrichment p-value. (**b**) SPP2genes in hepatocellular carcinoma.SPP2 is coexpressed with the indicated genes across a panel of 22 hepatocellular carcinoma and 21 normal tissues. Bar length represented the significance and negative logarithm of enrichment *p*-value

Discussion {#Sec14}
==========

To date, the detailed function and role of SPP in cancer development and metastasis are poorly understood. Therefore, we assessed, for the first time, the predictive value and expression patterns of SPP in various cancers. We are not able to define particular genes as tumor suppressor genes simply based on expression levels in the absence of explicit mechanistic studies, however, tapping into extensive oncogenic databases can provide researchers with a deeper understanding of the molecular mechanisms of these genes. Analysis of the relationship between SPP1 and the prognosis of various tumors revealed that SPP1 was upregulated in breast, bladder, colorectal, head and neck, liver, lung, and esophageal cancers. Further, high levels of SPP1 gene expression were associated with a poor prognosis for these cancers. SPP1 has been reported to enhance cancer cell survival, angiogenesis, and inflammation \[[@CR15]\], while also promoting metastasis by favoring epithelial-to-mesenchymal transition \[[@CR16]\]. This indicates that SPP1 is a tumor-promoting gene in these cancers. On the contrary, SPP2 was found to be deregulated in colorectal cancer, leukemia, liver cancer, and pancreatic cancer. Breast and lung cancer patients with high SPP2 expression had a better prognosis. BMPs contribute to the initiation and progression of multiple cancers. SPP2 has been shown to bind to BMP-2 and inhibit tumor growth through the blockage of BMP-2 \[[@CR9]\]. Thus, SPP2 may have great potential as a clinical therapeutic agent.

Our SPP PPI network offers valuable insight into predicted interactions and functional relationships between genes. Most of the primary biological processes of SPP genes and the 10 predicted genes were related to the mTOR signaling pathway and class I PI3K signaling events, as well as cell growth and maintenance, signaling transduction, cell communication, and protein metabolism. Given the key role of the mTOR pathway in cell growth, regulation of actin cytoskeleton, gene transcription, ribosome biogenesis, and mRNA translation, there appears to be a link between mTOR activation and cancer. PI3K activation may be important for KRAS-induced tumorigenesis. Alteration of these pathways is strongly implicated in cancer pathogenesis; thus, targeting the effectors of these pathways is a promising therapeutic approach \[[@CR17]\].

The cBioportal analysis revealed that SPP mutations and copy number alterations mainly occurred in prostate cancer, cutaneous melanoma, and endometrial cancer. It has been reported that somatically acquired genetics, epigenetics, transcriptomics, and proteomics are the main causes of cellular carcinogenesis. These changes may lead to suppression or carcinogenesis \[[@CR18]\]. Co-expression analyses indicated that SPP1 was co-expressed with MMP9, ARPC1B, and APP in head-neck cancer. These results indicate that these genes have similar functions in head and neck cancer, and jointly promote tumorigenesis. SPP2 was co-expressed with LECT2, CPS1, and Ribokinase in hepatocellular carcinoma. This indicates that SPP2, LECT2, CPS1, and Ribokinase exert tumor suppressive effects in hepatocellular carcinoma.

Conclusion {#Sec15}
==========

To the best of our knowledge, the present study is the first to assess the importance and function of SPP family genes in the context of cancer development. Our systematic analysis of the expression and predictive value of SPP genes in various cancer types provided new insight into the heterogeneous expression of these genes in various cancers. Our findings indicate that SPP1 and SPP2 genes might play an important role in cancer progression. SPP1 appears to correlate with poor clinical outcomes, whereas SPP2 appears to be a potential prognostic marker for better survival. The inhibition or activation of SPP genes as a therapeutic approach for cancer treatment is dependent on the type of cancer to be treated. Further research is required to explore the signaling pathways and potential mechanisms of SPP genes in cancer and other diseases.

Additional file
===============

 {#Sec16}

**Additional file 1: Figure S1.** The association between the expression of SPP genes and prognosis in cancers (Kaplan- Meier Plotter database), The prognostic value of SPP1 and SPP2 expression level in breast cancer (A, C) and ovarian cancer (B, D) was plotted from Kaplan- Meier Plotter database.
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